Time to Reconsider Tocagen Inc (NASDAQ:TOCA) After More Short Sellers?

June 12, 2018 - By Maria Brooks

The stock of Tocagen Inc (NASDAQ:TOCA) registered an increase of 5.06% in short interest. TOCA’s total short interest was 1.07 million shares in June as published by FINRA. Its up 5.06% from 1.02 million shares, reported previously. With 105,200 shares average volume, it will take short sellers 10 days to cover their TOCA’s short positions. The short interest to Tocagen Inc’s float is 7.15%.

The stock increased 5.14% or $0.4951 during the last trading session, reaching $10.1351. About 88,975 shares traded. Tocagen Inc. (NASDAQ:TOCA) has declined 44.41% since June 12, 2017 and is downtrending. It has underperformed by 56.98% the S&P500.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. The company has market cap of $201.82 million. The Company’s cancer-selective gene therapy platform is built on retroviral replicating vectors , which are designed to deliver therapeutic genes into the DNA of cancer cells. It currently has negative earnings. The company??s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG).

More recent Tocagen Inc. (NASDAQ:TOCA) news were published by: Benzinga.com which released: “B Riley Likes Tocagen On Prospects For Company’s Brain Cancer Drug” on May 16, 2018. Also Seekingalpha.com published the news titled: “Premarket analyst action – healthcare” on May 16, 2018. Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For June 11, 2018” with publication date: June 11, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.